Inflammatory Bowel Disease (IBD) is a term used to describe disorders that involve chronic inflammation of the digestive tract, including Crohn's Disease and Ulcerative Colitis. Below are COVID news and research updates that specifically relate to IBD.
Researchers evaluated the characteristics, severity, course of infection, and disease outcomes in COVID-19 patients with and without Systemic Autoimmune Rheumatic Diseases (SARDs). Patients with rheumatoid arthritis, systemic lupus erythematosus (SLE), Sjögren’s syndrome, Psoriasis, Type 1 Diabetes, Inflammatory Bowel Disease, and Glomerulonephritis, amongst others, were included in the study.
Read More »Autoimmune disease is currently considered a risk factor for severe COVID-19. A research article published in Rheumatology last Fall summarized 30-day outcomes of autoimmune disease (AD) patients following hospitalization with COVID-19. AD patients diagnosed and/or hospitalized between January and June 2020 with COVID-19 were included, and their 30 day outcomes were compared to patients with at least one AD hospitalized with influenza from September 2017 through April 2018.
Read More »A Comment piece was recently published in The Lancet regarding a small study evaluating the immunogenicity of the Pfizer COVID-19 vaccine in 17 axial spondyloarthritis patients on TNF or IL-17A inhibitors. “All patients were managed according to treatment guidelines; secukinumab (150 mg) was administered every four weeks, and adalimumab (40 mg) was administered either every 2 weeks or every three weeks.”
Read More »A study conducted out of Cedars-Sinai found that patients with IBD (ulcerative colitis and Crohn’s disease) produced strong antibodies following COVID-19 vaccination. Patients taking medications for other chronic inflammatory disorders have been observed to produce less antibodies depending on the medication they are taking to treat their autoimmune disease.
Read More »